Brief: Immuneering Announces FDA Clearance Of IND Application For Phase 1/2A Trial Of Imm-6-415 To Treat Advanced Solid Tumors With Raf Or Ras Mutations
12/12/2023 13:34
Dec 12 (Reuters) - Immuneering Corp IMRX.O :
* IMMUNEERING ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR
PHASE
1/2A TRIAL OF IMM-6-415 TO TREAT ADVANCED SOLID TUMORS WITH RAF
OR RAS MUTATIONS
* IMMUNEERING CORP: DOSING OF FIRST PATIENT IN PHASE 1/2A
CLINICAL
TRIAL EXPECTED IN EARLY 2024
Source text for Eikon: ID:nGNX2xS4S8
Further company coverage: IMRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immuneering
See all newsImmuneering expects cash runway to fund operations into 2029
Immuneering posts smaller-than-expected Q1 net loss on lower R&D spend
U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences